SLC6A6 and acute myeloid leukemia: SLC6A6 expression is also enriched in reactive oxygen species (ROS)-low LSCs from human monocytic AMLs (subtype clinically associated with venetoclax resistance; CD45brightSSChighCD117−CD11b+CD68+) compared with primitive AML (Fig. 4b; CD45medSSClowCD117+CD11b−CD68−)32.